#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Abnormal degree centrality in chronic users of codeine-containing cough syrups: A resting-state functional magnetic resonance imaging study Codeine-containing cough syrups (CCS) have become one of the most popular drugs of abuse in young population worldwide.
1-1	0-8	Abnormal	_
1-2	9-15	degree	_
1-3	16-26	centrality	_
1-4	27-29	in	_
1-5	30-37	chronic	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-6	38-43	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-7	44-46	of	_
1-8	47-65	codeine-containing	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-9	66-71	cough	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-10	72-78	syrups	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-11	79-80	:	_
1-12	81-82	A	_
1-13	83-96	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-14	97-107	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-15	108-116	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-16	117-126	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-17	127-134	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-18	135-140	study	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-19	141-159	Codeine-containing	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-20	160-165	cough	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-21	166-172	syrups	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-22	173-174	(	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-23	175-178	CCS	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-24	179-180	)	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-25	181-185	have	_
1-26	186-192	become	_
1-27	193-196	one	_
1-28	197-199	of	_
1-29	200-203	the	_
1-30	204-208	most	_
1-31	209-216	popular	_
1-32	217-222	drugs	_
1-33	223-225	of	_
1-34	226-231	abuse	_
1-35	232-234	in	_
1-36	235-240	young	_
1-37	241-251	population	_
1-38	252-261	worldwide	_
1-39	262-263	.	_

Text=However, the neurobiological mechanisms underlying CCS-dependence are yet ill-defined.
2-1	264-271	However	_
2-2	272-273	,	_
2-3	274-277	the	_
2-4	278-293	neurobiological	_
2-5	294-304	mechanisms	_
2-6	305-315	underlying	_
2-7	316-330	CCS-dependence	_
2-8	331-334	are	_
2-9	335-338	yet	_
2-10	339-350	ill-defined	_
2-11	351-352	.	_

Text=Therefore, understanding the brain abnormalities in chronic users of CCS is crucial for developing effective interventions.
3-1	353-362	Therefore	_
3-2	363-364	,	_
3-3	365-378	understanding	_
3-4	379-382	the	_
3-5	383-388	brain	_
3-6	389-402	abnormalities	_
3-7	403-405	in	_
3-8	406-413	chronic	_
3-9	414-419	users	_
3-10	420-422	of	_
3-11	423-426	CCS	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-12	427-429	is	_
3-13	430-437	crucial	_
3-14	438-441	for	_
3-15	442-452	developing	_
3-16	453-462	effective	_
3-17	463-476	interventions	_
3-18	477-478	.	_

Text=The present study depicted the intrinsic dysconnectivity pattern of whole-brain functional networks at the voxel level in chronic users of CCS.
4-1	479-482	The	_
4-2	483-490	present	_
4-3	491-496	study	_
4-4	497-505	depicted	_
4-5	506-509	the	_
4-6	510-519	intrinsic	_
4-7	520-535	dysconnectivity	_
4-8	536-543	pattern	_
4-9	544-546	of	_
4-10	547-558	whole-brain	_
4-11	559-569	functional	_
4-12	570-578	networks	_
4-13	579-581	at	_
4-14	582-585	the	_
4-15	586-591	voxel	_
4-16	592-597	level	_
4-17	598-600	in	_
4-18	601-608	chronic	_
4-19	609-614	users	_
4-20	615-617	of	_
4-21	618-621	CCS	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-22	622-623	.	_

Text=In addition, the degree centrality (DC) changes were correlated to the Barratt Impulsiveness Scale (BIS-11) total score, dose, duration of CCS use, and the age at first use of cough syrups.
5-1	624-626	In	_
5-2	627-635	addition	_
5-3	636-637	,	_
5-4	638-641	the	_
5-5	642-648	degree	_
5-6	649-659	centrality	_
5-7	660-661	(	_
5-8	662-664	DC	_
5-9	665-666	)	_
5-10	667-674	changes	_
5-11	675-679	were	_
5-12	680-690	correlated	_
5-13	691-693	to	_
5-14	694-697	the	_
5-15	698-705	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
5-16	706-719	Impulsiveness	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
5-17	720-725	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
5-18	726-727	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
5-19	728-734	BIS-11	_
5-20	735-736	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-21	737-742	total	_
5-22	743-748	score	_
5-23	749-750	,	_
5-24	751-755	dose	_
5-25	756-757	,	_
5-26	758-766	duration	_
5-27	767-769	of	_
5-28	770-773	CCS	_
5-29	774-777	use	_
5-30	778-779	,	_
5-31	780-783	and	_
5-32	784-787	the	_
5-33	788-791	age	_
5-34	792-794	at	_
5-35	795-800	first	_
5-36	801-804	use	_
5-37	805-807	of	_
5-38	808-813	cough	_
5-39	814-820	syrups	_
5-40	821-822	.	_

Text=The current study included 38 chronic CCS users and 34 matched control subjects.
6-1	823-826	The	_
6-2	827-834	current	_
6-3	835-840	study	_
6-4	841-849	included	_
6-5	850-852	38	_
6-6	853-860	chronic	_
6-7	861-864	CCS	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
6-8	865-870	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
6-9	871-874	and	_
6-10	875-877	34	_
6-11	878-885	matched	_
6-12	886-893	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-13	894-902	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-14	903-904	.	_

Text=All patients were evaluated using the BIS-11.
7-1	905-908	All	_
7-2	909-917	patients	_
7-3	918-922	were	_
7-4	923-932	evaluated	_
7-5	933-938	using	_
7-6	939-942	the	_
7-7	943-949	BIS-11	_
7-8	950-951	.	_

Text=Next, resting-state functional magnetic resonance imaging (rs-fMRI) datasets were acquired from these CCS users and controls.
8-1	952-956	Next	_
8-2	957-958	,	_
8-3	959-972	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-4	973-983	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-5	984-992	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-6	993-1002	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-7	1003-1010	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-8	1011-1012	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-9	1013-1020	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-10	1021-1022	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-11	1023-1031	datasets	_
8-12	1032-1036	were	_
8-13	1037-1045	acquired	_
8-14	1046-1050	from	_
8-15	1051-1056	these	_
8-16	1057-1060	CCS	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
8-17	1061-1066	users	_
8-18	1067-1070	and	_
8-19	1071-1079	controls	_
8-20	1080-1081	.	_

Text=Whole-brain connectivity was analyzed using a graph theory approach: degree centrality (DC).
9-1	1082-1093	Whole-brain	_
9-2	1094-1106	connectivity	_
9-3	1107-1110	was	_
9-4	1111-1119	analyzed	_
9-5	1120-1125	using	_
9-6	1126-1127	a	_
9-7	1128-1133	graph	_
9-8	1134-1140	theory	_
9-9	1141-1149	approach	_
9-10	1150-1151	:	_
9-11	1152-1158	degree	_
9-12	1159-1169	centrality	_
9-13	1170-1171	(	_
9-14	1172-1174	DC	_
9-15	1175-1176	)	_
9-16	1177-1178	.	_

Text=CCS-dependent individuals exhibited low DC values in the left inferior parietal lobule and the left middle temporal gyrus, while high DC values were noted in the right pallidum and the right hippocampus (P <0.01, AlphaSim corrected).
10-1	1179-1192	CCS-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
10-2	1193-1204	individuals	_
10-3	1205-1214	exhibited	_
10-4	1215-1218	low	_
10-5	1219-1221	DC	_
10-6	1222-1228	values	_
10-7	1229-1231	in	_
10-8	1232-1235	the	_
10-9	1236-1240	left	_
10-10	1241-1249	inferior	_
10-11	1250-1258	parietal	_
10-12	1259-1265	lobule	_
10-13	1266-1269	and	_
10-14	1270-1273	the	_
10-15	1274-1278	left	_
10-16	1279-1285	middle	_
10-17	1286-1294	temporal	_
10-18	1295-1300	gyrus	_
10-19	1301-1302	,	_
10-20	1303-1308	while	_
10-21	1309-1313	high	_
10-22	1314-1316	DC	_
10-23	1317-1323	values	_
10-24	1324-1328	were	_
10-25	1329-1334	noted	_
10-26	1335-1337	in	_
10-27	1338-1341	the	_
10-28	1342-1347	right	_
10-29	1348-1356	pallidum	_
10-30	1357-1360	and	_
10-31	1361-1364	the	_
10-32	1365-1370	right	_
10-33	1371-1382	hippocampus	_
10-34	1383-1384	(	_
10-35	1385-1386	P	_
10-36	1387-1388	<	_
10-37	1389-1393	0.01	_
10-38	1394-1395	,	_
10-39	1396-1404	AlphaSim	_
10-40	1405-1414	corrected	_
10-41	1415-1416	)	_
10-42	1417-1418	.	_

Text=Also, significant correlations were established between average DC value in the left inferior parietal lobule and attentional impulsivity scores and the age at first CCS use.
11-1	1419-1423	Also	_
11-2	1424-1425	,	_
11-3	1426-1437	significant	_
11-4	1438-1450	correlations	_
11-5	1451-1455	were	_
11-6	1456-1467	established	_
11-7	1468-1475	between	_
11-8	1476-1483	average	_
11-9	1484-1486	DC	_
11-10	1487-1492	value	_
11-11	1493-1495	in	_
11-12	1496-1499	the	_
11-13	1500-1504	left	_
11-14	1505-1513	inferior	_
11-15	1514-1522	parietal	_
11-16	1523-1529	lobule	_
11-17	1530-1533	and	_
11-18	1534-1545	attentional	_
11-19	1546-1557	impulsivity	_
11-20	1558-1564	scores	_
11-21	1565-1568	and	_
11-22	1569-1572	the	_
11-23	1573-1576	age	_
11-24	1577-1579	at	_
11-25	1580-1585	first	_
11-26	1586-1589	CCS	_
11-27	1590-1593	use	_
11-28	1594-1595	.	_

Text=The rs-fMRI study suggested that the abnormal intrinsic dysconnectivity pattern of whole-brain functional networks may provide an insight into the neural substrates of abnormalities in the cognitive control circuit, the reward circuit, and the learning and memory circuit in CCS-dependent individuals.
12-1	1596-1599	The	_
12-2	1600-1607	rs-fMRI	_
12-3	1608-1613	study	_
12-4	1614-1623	suggested	_
12-5	1624-1628	that	_
12-6	1629-1632	the	_
12-7	1633-1641	abnormal	_
12-8	1642-1651	intrinsic	_
12-9	1652-1667	dysconnectivity	_
12-10	1668-1675	pattern	_
12-11	1676-1678	of	_
12-12	1679-1690	whole-brain	_
12-13	1691-1701	functional	_
12-14	1702-1710	networks	_
12-15	1711-1714	may	_
12-16	1715-1722	provide	_
12-17	1723-1725	an	_
12-18	1726-1733	insight	_
12-19	1734-1738	into	_
12-20	1739-1742	the	_
12-21	1743-1749	neural	_
12-22	1750-1760	substrates	_
12-23	1761-1763	of	_
12-24	1764-1777	abnormalities	_
12-25	1778-1780	in	_
12-26	1781-1784	the	_
12-27	1785-1794	cognitive	_
12-28	1795-1802	control	_
12-29	1803-1810	circuit	_
12-30	1811-1812	,	_
12-31	1813-1816	the	_
12-32	1817-1823	reward	_
12-33	1824-1831	circuit	_
12-34	1832-1833	,	_
12-35	1834-1837	and	_
12-36	1838-1841	the	_
12-37	1842-1850	learning	_
12-38	1851-1854	and	_
12-39	1855-1861	memory	_
12-40	1862-1869	circuit	_
12-41	1870-1872	in	_
12-42	1873-1886	CCS-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
12-43	1887-1898	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
12-44	1899-1900	.	_

Text=Highlights The abuse of CCS has gained a severe foothold among young individuals worldwide.
13-1	1901-1911	Highlights	_
13-2	1912-1915	The	_
13-3	1916-1921	abuse	_
13-4	1922-1924	of	_
13-5	1925-1928	CCS	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
13-6	1929-1932	has	_
13-7	1933-1939	gained	_
13-8	1940-1941	a	_
13-9	1942-1948	severe	_
13-10	1949-1957	foothold	_
13-11	1958-1963	among	_
13-12	1964-1969	young	_
13-13	1970-1981	individuals	_
13-14	1982-1991	worldwide	_
13-15	1992-1993	.	_

Text=DC is one of the more reliable and compelling measures among several nodal network metrics.
14-1	1994-1996	DC	_
14-2	1997-1999	is	_
14-3	2000-2003	one	_
14-4	2004-2006	of	_
14-5	2007-2010	the	_
14-6	2011-2015	more	_
14-7	2016-2024	reliable	_
14-8	2025-2028	and	_
14-9	2029-2039	compelling	_
14-10	2040-2048	measures	_
14-11	2049-2054	among	_
14-12	2055-2062	several	_
14-13	2063-2068	nodal	_
14-14	2069-2076	network	_
14-15	2077-2084	metrics	_
14-16	2085-2086	.	_

Text=The present study depicted intrinsic dysconnectivity pattern of whole-brain functional networks in CCS-dependent individuals.
15-1	2087-2090	The	_
15-2	2091-2098	present	_
15-3	2099-2104	study	_
15-4	2105-2113	depicted	_
15-5	2114-2123	intrinsic	_
15-6	2124-2139	dysconnectivity	_
15-7	2140-2147	pattern	_
15-8	2148-2150	of	_
15-9	2151-2162	whole-brain	_
15-10	2163-2173	functional	_
15-11	2174-2182	networks	_
15-12	2183-2185	in	_
15-13	2186-2199	CCS-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
15-14	2200-2211	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
15-15	2212-2213	.	_

Text=CCS-dependent individuals showed altered DC in the right pallidum, right hippocampus, left IPL and left middle temporal gyrus.
16-1	2214-2227	CCS-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
16-2	2228-2239	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
16-3	2240-2246	showed	_
16-4	2247-2254	altered	_
16-5	2255-2257	DC	_
16-6	2258-2260	in	_
16-7	2261-2264	the	_
16-8	2265-2270	right	_
16-9	2271-2279	pallidum	_
16-10	2280-2281	,	_
16-11	2282-2287	right	_
16-12	2288-2299	hippocampus	_
16-13	2300-2301	,	_
16-14	2302-2306	left	_
16-15	2307-2310	IPL	_
16-16	2311-2314	and	_
16-17	2315-2319	left	_
16-18	2320-2326	middle	_
16-19	2327-2335	temporal	_
16-20	2336-2341	gyrus	_
16-21	2342-2343	.	_

Text=Significant correlations were established between average DC value in the left IPL and attentional impulsivity scores and the age at first CCS use.
17-1	2344-2355	Significant	_
17-2	2356-2368	correlations	_
17-3	2369-2373	were	_
17-4	2374-2385	established	_
17-5	2386-2393	between	_
17-6	2394-2401	average	_
17-7	2402-2404	DC	_
17-8	2405-2410	value	_
17-9	2411-2413	in	_
17-10	2414-2417	the	_
17-11	2418-2422	left	_
17-12	2423-2426	IPL	_
17-13	2427-2430	and	_
17-14	2431-2442	attentional	_
17-15	2443-2454	impulsivity	_
17-16	2455-2461	scores	_
17-17	2462-2465	and	_
17-18	2466-2469	the	_
17-19	2470-2473	age	_
17-20	2474-2476	at	_
17-21	2477-2482	first	_
17-22	2483-2486	CCS	_
17-23	2487-2490	use	_
17-24	2491-2492	.	_

Text=Materials and methods Participants This prospective study was approved by the Ethics Committee of Guangdong Second Provincial General Hospital.
18-1	2493-2502	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
18-2	2503-2506	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
18-3	2507-2514	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
18-4	2515-2527	Participants	_
18-5	2528-2532	This	_
18-6	2533-2544	prospective	_
18-7	2545-2550	study	_
18-8	2551-2554	was	_
18-9	2555-2563	approved	_
18-10	2564-2566	by	_
18-11	2567-2570	the	_
18-12	2571-2577	Ethics	_
18-13	2578-2587	Committee	_
18-14	2588-2590	of	_
18-15	2591-2600	Guangdong	_
18-16	2601-2607	Second	_
18-17	2608-2618	Provincial	_
18-18	2619-2626	General	_
18-19	2627-2635	Hospital	_
18-20	2636-2637	.	_

Text=Written informed consent was obtained from all subjects.
19-1	2638-2645	Written	_
19-2	2646-2654	informed	_
19-3	2655-2662	consent	_
19-4	2663-2666	was	_
19-5	2667-2675	obtained	_
19-6	2676-2680	from	_
19-7	2681-2684	all	_
19-8	2685-2693	subjects	_
19-9	2694-2695	.	_

Text=A total of 72 right-handed participants, including 34 control subjects and 38 CCS-dependent individuals, were enrolled in this study.
20-1	2696-2697	A	_
20-2	2698-2703	total	_
20-3	2704-2706	of	_
20-4	2707-2709	72	_
20-5	2710-2722	right-handed	_
20-6	2723-2735	participants	_
20-7	2736-2737	,	_
20-8	2738-2747	including	_
20-9	2748-2750	34	_
20-10	2751-2758	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
20-11	2759-2767	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
20-12	2768-2771	and	_
20-13	2772-2774	38	_
20-14	2775-2788	CCS-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
20-15	2789-2800	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
20-16	2801-2802	,	_
20-17	2803-2807	were	_
20-18	2808-2816	enrolled	_
20-19	2817-2819	in	_
20-20	2820-2824	this	_
20-21	2825-2830	study	_
20-22	2831-2832	.	_

Text=The CCS-dependent individuals were recruited from the patients seeking treatment at the Addiction Medicine Division of the Guangdong Second Provincial General Hospital.
21-1	2833-2836	The	_
21-2	2837-2850	CCS-dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
21-3	2851-2862	individuals	_
21-4	2863-2867	were	_
21-5	2868-2877	recruited	_
21-6	2878-2882	from	_
21-7	2883-2886	the	_
21-8	2887-2895	patients	_
21-9	2896-2903	seeking	_
21-10	2904-2913	treatment	_
21-11	2914-2916	at	_
21-12	2917-2920	the	_
21-13	2921-2930	Addiction	_
21-14	2931-2939	Medicine	_
21-15	2940-2948	Division	_
21-16	2949-2951	of	_
21-17	2952-2955	the	_
21-18	2956-2965	Guangdong	_
21-19	2966-2972	Second	_
21-20	2973-2983	Provincial	_
21-21	2984-2991	General	_
21-22	2992-3000	Hospital	_
21-23	3001-3002	.	_

Text=All the patients were screened based on the DSM-IV criteria from medical history and underwent a urine test and an interview on the same day.
22-1	3003-3006	All	_
22-2	3007-3010	the	_
22-3	3011-3019	patients	_
22-4	3020-3024	were	_
22-5	3025-3033	screened	_
22-6	3034-3039	based	_
22-7	3040-3042	on	_
22-8	3043-3046	the	_
22-9	3047-3053	DSM-IV	_
22-10	3054-3062	criteria	_
22-11	3063-3067	from	_
22-12	3068-3075	medical	_
22-13	3076-3083	history	_
22-14	3084-3087	and	_
22-15	3088-3097	underwent	_
22-16	3098-3099	a	_
22-17	3100-3105	urine	_
22-18	3106-3110	test	_
22-19	3111-3114	and	_
22-20	3115-3117	an	_
22-21	3118-3127	interview	_
22-22	3128-3130	on	_
22-23	3131-3134	the	_
22-24	3135-3139	same	_
22-25	3140-3143	day	_
22-26	3144-3145	.	_

Text=All participants regularly smoked cigarettes but did not use any type of psychotropic agents prior to the rs-fMRI scan.
23-1	3146-3149	All	_
23-2	3150-3162	participants	_
23-3	3163-3172	regularly	_
23-4	3173-3179	smoked	_
23-5	3180-3190	cigarettes	_
23-6	3191-3194	but	_
23-7	3195-3198	did	_
23-8	3199-3202	not	_
23-9	3203-3206	use	_
23-10	3207-3210	any	_
23-11	3211-3215	type	_
23-12	3216-3218	of	_
23-13	3219-3231	psychotropic	_
23-14	3232-3238	agents	_
23-15	3239-3244	prior	_
23-16	3245-3247	to	_
23-17	3248-3251	the	_
23-18	3252-3259	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
23-19	3260-3264	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
23-20	3265-3266	.	_

Text=The exclusion criteria for all participants included central nervous system diseases, schizophrenia, bipolar disorder, prior significant head trauma, positive human immunodeficiency virus (HIV) status, diabetes, hepatitis C, other major medical illness, and left-handedness.
24-1	3267-3270	The	_
24-2	3271-3280	exclusion	_
24-3	3281-3289	criteria	_
24-4	3290-3293	for	_
24-5	3294-3297	all	_
24-6	3298-3310	participants	_
24-7	3311-3319	included	_
24-8	3320-3327	central	_
24-9	3328-3335	nervous	_
24-10	3336-3342	system	_
24-11	3343-3351	diseases	_
24-12	3352-3353	,	_
24-13	3354-3367	schizophrenia	_
24-14	3368-3369	,	_
24-15	3370-3377	bipolar	_
24-16	3378-3386	disorder	_
24-17	3387-3388	,	_
24-18	3389-3394	prior	_
24-19	3395-3406	significant	_
24-20	3407-3411	head	_
24-21	3412-3418	trauma	_
24-22	3419-3420	,	_
24-23	3421-3429	positive	_
24-24	3430-3435	human	_
24-25	3436-3452	immunodeficiency	_
24-26	3453-3458	virus	_
24-27	3459-3460	(	_
24-28	3461-3464	HIV	_
24-29	3465-3466	)	_
24-30	3467-3473	status	_
24-31	3474-3475	,	_
24-32	3476-3484	diabetes	_
24-33	3485-3486	,	_
24-34	3487-3496	hepatitis	_
24-35	3497-3498	C	_
24-36	3499-3500	,	_
24-37	3501-3506	other	_
24-38	3507-3512	major	_
24-39	3513-3520	medical	_
24-40	3521-3528	illness	_
24-41	3529-3530	,	_
24-42	3531-3534	and	_
24-43	3535-3550	left-handedness	_
24-44	3551-3552	.	_

Text=The inclusion criteria for the control subjects was the absence of diagnosis of any type of substance abuse or dependence.
25-1	3553-3556	The	_
25-2	3557-3566	inclusion	_
25-3	3567-3575	criteria	_
25-4	3576-3579	for	_
25-5	3580-3583	the	_
25-6	3584-3591	control	_
25-7	3592-3600	subjects	_
25-8	3601-3604	was	_
25-9	3605-3608	the	_
25-10	3609-3616	absence	_
25-11	3617-3619	of	_
25-12	3620-3629	diagnosis	_
25-13	3630-3632	of	_
25-14	3633-3636	any	_
25-15	3637-3641	type	_
25-16	3642-3644	of	_
25-17	3645-3654	substance	_
25-18	3655-3660	abuse	_
25-19	3661-3663	or	_
25-20	3664-3674	dependence	_
25-21	3675-3676	.	_

Text=Impulsivity assessment BIS-11 was used for assessing the impulsivity.
26-1	3677-3688	Impulsivity	_
26-2	3689-3699	assessment	_
26-3	3700-3706	BIS-11	_
26-4	3707-3710	was	_
26-5	3711-3715	used	_
26-6	3716-3719	for	_
26-7	3720-3729	assessing	_
26-8	3730-3733	the	_
26-9	3734-3745	impulsivity	_
26-10	3746-3747	.	_

Text=This 30-item self-rated scale has three oblique factors: attentional/cognitive that measures the toleration for cognitive complexity and persistence; motor that estimates the tendency to act on the spur of the moment; and non-planning impulsivity, which evaluates the lack of sense of the future.
27-1	3748-3752	This	_
27-2	3753-3760	30-item	_
27-3	3761-3771	self-rated	_
27-4	3772-3777	scale	_
27-5	3778-3781	has	_
27-6	3782-3787	three	_
27-7	3788-3795	oblique	_
27-8	3796-3803	factors	_
27-9	3804-3805	:	_
27-10	3806-3827	attentional/cognitive	_
27-11	3828-3832	that	_
27-12	3833-3841	measures	_
27-13	3842-3845	the	_
27-14	3846-3856	toleration	_
27-15	3857-3860	for	_
27-16	3861-3870	cognitive	_
27-17	3871-3881	complexity	_
27-18	3882-3885	and	_
27-19	3886-3897	persistence	_
27-20	3898-3899	;	_
27-21	3900-3905	motor	_
27-22	3906-3910	that	_
27-23	3911-3920	estimates	_
27-24	3921-3924	the	_
27-25	3925-3933	tendency	_
27-26	3934-3936	to	_
27-27	3937-3940	act	_
27-28	3941-3943	on	_
27-29	3944-3947	the	_
27-30	3948-3952	spur	_
27-31	3953-3955	of	_
27-32	3956-3959	the	_
27-33	3960-3966	moment	_
27-34	3967-3968	;	_
27-35	3969-3972	and	_
27-36	3973-3985	non-planning	_
27-37	3986-3997	impulsivity	_
27-38	3998-3999	,	_
27-39	4000-4005	which	_
27-40	4006-4015	evaluates	_
27-41	4016-4019	the	_
27-42	4020-4024	lack	_
27-43	4025-4027	of	_
27-44	4028-4033	sense	_
27-45	4034-4036	of	_
27-46	4037-4040	the	_
27-47	4041-4047	future	_
27-48	4048-4049	.	_

Text=Items are rated from 1 (rarely/never) to 4 (almost always/always).
28-1	4050-4055	Items	_
28-2	4056-4059	are	_
28-3	4060-4065	rated	_
28-4	4066-4070	from	_
28-5	4071-4072	1	_
28-6	4073-4074	(	_
28-7	4075-4087	rarely/never	_
28-8	4088-4089	)	_
28-9	4090-4092	to	_
28-10	4093-4094	4	_
28-11	4095-4096	(	_
28-12	4097-4103	almost	_
28-13	4104-4117	always/always	_
28-14	4118-4119	)	_
28-15	4120-4121	.	_

Text=To determine the overall impulsiveness scores, all items are summed; high scores indicate remarkable impulsivity.
29-1	4122-4124	To	_
29-2	4125-4134	determine	_
29-3	4135-4138	the	_
29-4	4139-4146	overall	_
29-5	4147-4160	impulsiveness	_
29-6	4161-4167	scores	_
29-7	4168-4169	,	_
29-8	4170-4173	all	_
29-9	4174-4179	items	_
29-10	4180-4183	are	_
29-11	4184-4190	summed	_
29-12	4191-4192	;	_
29-13	4193-4197	high	_
29-14	4198-4204	scores	_
29-15	4205-4213	indicate	_
29-16	4214-4224	remarkable	_
29-17	4225-4236	impulsivity	_
29-18	4237-4238	.	_

Text=BIS-11 is a valid and reliable instrument for healthy Chinese and psychiatric populations.
30-1	4239-4245	BIS-11	_
30-2	4246-4248	is	_
30-3	4249-4250	a	_
30-4	4251-4256	valid	_
30-5	4257-4260	and	_
30-6	4261-4269	reliable	_
30-7	4270-4280	instrument	_
30-8	4281-4284	for	_
30-9	4285-4292	healthy	_
30-10	4293-4300	Chinese	_
30-11	4301-4304	and	_
30-12	4305-4316	psychiatric	_
30-13	4317-4328	populations	_
30-14	4329-4330	.	_

Text=Data acquisition All MRI datasets were obtained using a Philips Achieva 1.5 T Nova dual MR scanner at the Department of Medical Imaging, Guangdong Second Provincial General Hospital.
31-1	4331-4335	Data	_
31-2	4336-4347	acquisition	_
31-3	4348-4351	All	_
31-4	4352-4355	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
31-5	4356-4364	datasets	_
31-6	4365-4369	were	_
31-7	4370-4378	obtained	_
31-8	4379-4384	using	_
31-9	4385-4386	a	_
31-10	4387-4394	Philips	_
31-11	4395-4402	Achieva	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
31-12	4403-4406	1.5	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
31-13	4407-4408	T	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
31-14	4409-4413	Nova	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
31-15	4414-4418	dual	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
31-16	4419-4421	MR	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
31-17	4422-4429	scanner	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
31-18	4430-4432	at	_
31-19	4433-4436	the	_
31-20	4437-4447	Department	_
31-21	4448-4450	of	_
31-22	4451-4458	Medical	_
31-23	4459-4466	Imaging	_
31-24	4467-4468	,	_
31-25	4469-4478	Guangdong	_
31-26	4479-4485	Second	_
31-27	4486-4496	Provincial	_
31-28	4497-4504	General	_
31-29	4505-4513	Hospital	_
31-30	4514-4515	.	_

Text=These datasets included rs-fMRI dataset and T1-weighted structural images.
32-1	4516-4521	These	_
32-2	4522-4530	datasets	_
32-3	4531-4539	included	_
32-4	4540-4547	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-5	4548-4555	dataset	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
32-6	4556-4559	and	_
32-7	4560-4571	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-8	4572-4582	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-9	4583-4589	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
32-10	4590-4591	.	_

Text=The rs-fMRI dataset [22 axial slices, repetition time (TR) /echo time (TE) = 2000 ms/50 ms, matrix = 64 × 64, field of view (FOV) = 230 × 230 mm2, slice thickness = 4.5 mm without gap, flip angle = 90°] was acquired using an echo planar imaging (EPI) sequence.
33-1	4592-4595	The	_
33-2	4596-4603	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
33-3	4604-4611	dataset	_
33-4	4612-4613	[	_
33-5	4614-4616	22	_
33-6	4617-4622	axial	_
33-7	4623-4629	slices	_
33-8	4630-4631	,	_
33-9	4632-4642	repetition	_
33-10	4643-4647	time	_
33-11	4648-4649	(	_
33-12	4650-4652	TR	_
33-13	4653-4654	)	_
33-14	4655-4660	/echo	_
33-15	4661-4665	time	_
33-16	4666-4667	(	_
33-17	4668-4670	TE	_
33-18	4671-4672	)	_
33-19	4673-4674	=	_
33-20	4675-4679	2000	_
33-21	4680-4685	ms/50	_
33-22	4686-4688	ms	_
33-23	4689-4690	,	_
33-24	4691-4697	matrix	_
33-25	4698-4699	=	_
33-26	4700-4702	64	_
33-27	4703-4704	×	_
33-28	4705-4707	64	_
33-29	4708-4709	,	_
33-30	4710-4715	field	_
33-31	4716-4718	of	_
33-32	4719-4723	view	_
33-33	4724-4725	(	_
33-34	4726-4729	FOV	_
33-35	4730-4731	)	_
33-36	4732-4733	=	_
33-37	4734-4737	230	_
33-38	4738-4739	×	_
33-39	4740-4743	230	_
33-40	4744-4747	mm2	_
33-41	4748-4749	,	_
33-42	4750-4755	slice	_
33-43	4756-4765	thickness	_
33-44	4766-4767	=	_
33-45	4768-4771	4.5	_
33-46	4772-4774	mm	_
33-47	4775-4782	without	_
33-48	4783-4786	gap	_
33-49	4787-4788	,	_
33-50	4789-4793	flip	_
33-51	4794-4799	angle	_
33-52	4800-4801	=	_
33-53	4802-4805	90°	_
33-54	4806-4807	]	_
33-55	4808-4811	was	_
33-56	4812-4820	acquired	_
33-57	4821-4826	using	_
33-58	4827-4829	an	_
33-59	4830-4834	echo	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
33-60	4835-4841	planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
33-61	4842-4849	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
33-62	4850-4851	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
33-63	4852-4855	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
33-64	4856-4857	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
33-65	4858-4866	sequence	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
33-66	4867-4868	.	_

Text=Each functional run contained 240 volumes (8 min) [the slices were approximately along the anterior commissure-posterior commissure (AC-PC) line and covered approximately 230 to 60 in the inferosuperior direction], and the subjects were asked to lie quietly with their eyes closed and avoid eye movement or thinking of anything specific or falling asleep while in the scanner, during the rs-fMRI data acquisition.
34-1	4869-4873	Each	_
34-2	4874-4884	functional	_
34-3	4885-4888	run	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
34-4	4889-4898	contained	_
34-5	4899-4902	240	_
34-6	4903-4910	volumes	_
34-7	4911-4912	(	_
34-8	4913-4914	8	_
34-9	4915-4918	min	_
34-10	4919-4920	)	_
34-11	4921-4922	[	_
34-12	4923-4926	the	_
34-13	4927-4933	slices	_
34-14	4934-4938	were	_
34-15	4939-4952	approximately	_
34-16	4953-4958	along	_
34-17	4959-4962	the	_
34-18	4963-4971	anterior	_
34-19	4972-4992	commissure-posterior	_
34-20	4993-5003	commissure	_
34-21	5004-5005	(	_
34-22	5006-5011	AC-PC	_
34-23	5012-5013	)	_
34-24	5014-5018	line	_
34-25	5019-5022	and	_
34-26	5023-5030	covered	_
34-27	5031-5044	approximately	_
34-28	5045-5048	230	_
34-29	5049-5051	to	_
34-30	5052-5054	60	_
34-31	5055-5057	in	_
34-32	5058-5061	the	_
34-33	5062-5076	inferosuperior	_
34-34	5077-5086	direction	_
34-35	5087-5088	]	_
34-36	5089-5090	,	_
34-37	5091-5094	and	_
34-38	5095-5098	the	_
34-39	5099-5107	subjects	_
34-40	5108-5112	were	_
34-41	5113-5118	asked	_
34-42	5119-5121	to	_
34-43	5122-5125	lie	_
34-44	5126-5133	quietly	_
34-45	5134-5138	with	_
34-46	5139-5144	their	_
34-47	5145-5149	eyes	_
34-48	5150-5156	closed	_
34-49	5157-5160	and	_
34-50	5161-5166	avoid	_
34-51	5167-5170	eye	_
34-52	5171-5179	movement	_
34-53	5180-5182	or	_
34-54	5183-5191	thinking	_
34-55	5192-5194	of	_
34-56	5195-5203	anything	_
34-57	5204-5212	specific	_
34-58	5213-5215	or	_
34-59	5216-5223	falling	_
34-60	5224-5230	asleep	_
34-61	5231-5236	while	_
34-62	5237-5239	in	_
34-63	5240-5243	the	_
34-64	5244-5251	scanner	_
34-65	5252-5253	,	_
34-66	5254-5260	during	_
34-67	5261-5264	the	_
34-68	5265-5272	rs-fMRI	_
34-69	5273-5277	data	_
34-70	5278-5289	acquisition	_
34-71	5290-5291	.	_

Text=Sagittal structural images (160 sagittal slices, TR/TE = 25 ms/4.1 ms, thickness = 1.0 mm, no gap, in-plane resolution = 231 × 232, FOV = 230 × 230 mm, flip angle = 30°) were acquired using a fast field echo (FFE) three-dimensional (3D) T1-weighted sequence.
35-1	5292-5300	Sagittal	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
35-2	5301-5311	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
35-3	5312-5318	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
35-4	5319-5320	(	_
35-5	5321-5324	160	_
35-6	5325-5333	sagittal	_
35-7	5334-5340	slices	_
35-8	5341-5342	,	_
35-9	5343-5348	TR/TE	_
35-10	5349-5350	=	_
35-11	5351-5353	25	_
35-12	5354-5360	ms/4.1	_
35-13	5361-5363	ms	_
35-14	5364-5365	,	_
35-15	5366-5375	thickness	_
35-16	5376-5377	=	_
35-17	5378-5381	1.0	_
35-18	5382-5384	mm	_
35-19	5385-5386	,	_
35-20	5387-5389	no	_
35-21	5390-5393	gap	_
35-22	5394-5395	,	_
35-23	5396-5404	in-plane	_
35-24	5405-5415	resolution	_
35-25	5416-5417	=	_
35-26	5418-5421	231	_
35-27	5422-5423	×	_
35-28	5424-5427	232	_
35-29	5428-5429	,	_
35-30	5430-5433	FOV	_
35-31	5434-5435	=	_
35-32	5436-5439	230	_
35-33	5440-5441	×	_
35-34	5442-5445	230	_
35-35	5446-5448	mm	_
35-36	5449-5450	,	_
35-37	5451-5455	flip	_
35-38	5456-5461	angle	_
35-39	5462-5463	=	_
35-40	5464-5467	30°	_
35-41	5468-5469	)	_
35-42	5470-5474	were	_
35-43	5475-5483	acquired	_
35-44	5484-5489	using	_
35-45	5490-5491	a	_
35-46	5492-5496	fast	_
35-47	5497-5502	field	_
35-48	5503-5507	echo	_
35-49	5508-5509	(	_
35-50	5510-5513	FFE	_
35-51	5514-5515	)	_
35-52	5516-5533	three-dimensional	_
35-53	5534-5535	(	_
35-54	5536-5538	3D	_
35-55	5539-5540	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
35-56	5541-5552	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-57	5553-5561	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
35-58	5562-5563	.	_

Text=Data pre-processing and DC calculation Data Processing Assistant for Resting-State Functional MR Imaging toolbox (http: //www.restfmri.net.sci-hub.cc/forum/DPARSF,) was used for the post-processing of the imaging data.
36-1	5564-5568	Data	_
36-2	5569-5583	pre-processing	_
36-3	5584-5587	and	_
36-4	5588-5590	DC	_
36-5	5591-5602	calculation	_
36-6	5603-5607	Data	_
36-7	5608-5618	Processing	_
36-8	5619-5628	Assistant	_
36-9	5629-5632	for	_
36-10	5633-5646	Resting-State	_
36-11	5647-5657	Functional	_
36-12	5658-5660	MR	_
36-13	5661-5668	Imaging	_
36-14	5669-5676	toolbox	_
36-15	5677-5678	(	_
36-16	5679-5683	http	_
36-17	5684-5685	:	_
36-18	5686-5728	//www.restfmri.net.sci-hub.cc/forum/DPARSF	_
36-19	5729-5730	,	_
36-20	5731-5732	)	_
36-21	5733-5736	was	_
36-22	5737-5741	used	_
36-23	5742-5745	for	_
36-24	5746-5749	the	_
36-25	5750-5765	post-processing	_
36-26	5766-5768	of	_
36-27	5769-5772	the	_
36-28	5773-5780	imaging	_
36-29	5781-5785	data	_
36-30	5786-5787	.	_

Text=Before pre-processing, the first 10 volumes were discarded for each subject so that magnetization reached a steady state and subjects adapted to the MRI scanning noise.
37-1	5788-5794	Before	_
37-2	5795-5809	pre-processing	_
37-3	5810-5811	,	_
37-4	5812-5815	the	_
37-5	5816-5821	first	_
37-6	5822-5824	10	_
37-7	5825-5832	volumes	_
37-8	5833-5837	were	_
37-9	5838-5847	discarded	_
37-10	5848-5851	for	_
37-11	5852-5856	each	_
37-12	5857-5864	subject	_
37-13	5865-5867	so	_
37-14	5868-5872	that	_
37-15	5873-5886	magnetization	_
37-16	5887-5894	reached	_
37-17	5895-5896	a	_
37-18	5897-5903	steady	_
37-19	5904-5909	state	_
37-20	5910-5913	and	_
37-21	5914-5922	subjects	_
37-22	5923-5930	adapted	_
37-23	5931-5933	to	_
37-24	5934-5937	the	_
37-25	5938-5941	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
37-26	5942-5950	scanning	_
37-27	5951-5956	noise	_
37-28	5957-5958	.	_

Text=Then, the remaining 230 fMRI images were obtained with slice time correction for the acquisition time delay and realignment of the head motion correction.
38-1	5959-5963	Then	_
38-2	5964-5965	,	_
38-3	5966-5969	the	_
38-4	5970-5979	remaining	_
38-5	5980-5983	230	_
38-6	5984-5988	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
38-7	5989-5995	images	_
38-8	5996-6000	were	_
38-9	6001-6009	obtained	_
38-10	6010-6014	with	_
38-11	6015-6020	slice	_
38-12	6021-6025	time	_
38-13	6026-6036	correction	_
38-14	6037-6040	for	_
38-15	6041-6044	the	_
38-16	6045-6056	acquisition	_
38-17	6057-6061	time	_
38-18	6062-6067	delay	_
38-19	6068-6071	and	_
38-20	6072-6083	realignment	_
38-21	6084-6086	of	_
38-22	6087-6090	the	_
38-23	6091-6095	head	_
38-24	6096-6102	motion	_
38-25	6103-6113	correction	_
38-26	6114-6115	.	_

Text=One patient and two control subjects, who showed head motion> 1.5 mm or 1.5° during image acquisition, were excluded in subsequent analysis.
39-1	6116-6119	One	_
39-2	6120-6127	patient	_
39-3	6128-6131	and	_
39-4	6132-6135	two	_
39-5	6136-6143	control	_
39-6	6144-6152	subjects	_
39-7	6153-6154	,	_
39-8	6155-6158	who	_
39-9	6159-6165	showed	_
39-10	6166-6170	head	_
39-11	6171-6177	motion	_
39-12	6178-6179	>	_
39-13	6180-6183	1.5	_
39-14	6184-6186	mm	_
39-15	6187-6189	or	_
39-16	6190-6194	1.5°	_
39-17	6195-6201	during	_
39-18	6202-6207	image	_
39-19	6208-6219	acquisition	_
39-20	6220-6221	,	_
39-21	6222-6226	were	_
39-22	6227-6235	excluded	_
39-23	6236-6238	in	_
39-24	6239-6249	subsequent	_
39-25	6250-6258	analysis	_
39-26	6259-6260	.	_

Text=All realigned images were normalized to the standard Montreal Neurological Institute (MNI) template by applying the echo planar imaging (EPI) template at a 3 × 3 × 3 mm3 resolution.
40-1	6261-6264	All	_
40-2	6265-6274	realigned	_
40-3	6275-6281	images	_
40-4	6282-6286	were	_
40-5	6287-6297	normalized	_
40-6	6298-6300	to	_
40-7	6301-6304	the	_
40-8	6305-6313	standard	_
40-9	6314-6322	Montreal	_
40-10	6323-6335	Neurological	_
40-11	6336-6345	Institute	_
40-12	6346-6347	(	_
40-13	6348-6351	MNI	_
40-14	6352-6353	)	_
40-15	6354-6362	template	_
40-16	6363-6365	by	_
40-17	6366-6374	applying	_
40-18	6375-6378	the	_
40-19	6379-6383	echo	_
40-20	6384-6390	planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-21	6391-6398	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-22	6399-6400	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-23	6401-6404	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-24	6405-6406	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-25	6407-6415	template	_
40-26	6416-6418	at	_
40-27	6419-6420	a	_
40-28	6421-6422	3	_
40-29	6423-6424	×	_
40-30	6425-6426	3	_
40-31	6427-6428	×	_
40-32	6429-6430	3	_
40-33	6431-6434	mm3	_
40-34	6435-6445	resolution	_
40-35	6446-6447	.	_

Text=The normalized functional image was subjected to spatial smoothing [6 mm half high full-width (FWHM) Gaussian kernel].
41-1	6448-6451	The	_
41-2	6452-6462	normalized	_
41-3	6463-6473	functional	_
41-4	6474-6479	image	_
41-5	6480-6483	was	_
41-6	6484-6493	subjected	_
41-7	6494-6496	to	_
41-8	6497-6504	spatial	_
41-9	6505-6514	smoothing	_
41-10	6515-6516	[	_
41-11	6517-6518	6	_
41-12	6519-6521	mm	_
41-13	6522-6526	half	_
41-14	6527-6531	high	_
41-15	6532-6542	full-width	_
41-16	6543-6544	(	_
41-17	6545-6549	FWHM	_
41-18	6550-6551	)	_
41-19	6552-6560	Gaussian	_
41-20	6561-6567	kernel	_
41-21	6568-6569	]	_
41-22	6570-6571	.	_

Text=Finally, the imaging data were processed to remove the linear trends and filtered using typical temporal bandpass (0.01–0.08 Hz) to reduce the low-frequency drift and high-frequency noise.
42-1	6572-6579	Finally	_
42-2	6580-6581	,	_
42-3	6582-6585	the	_
42-4	6586-6593	imaging	_
42-5	6594-6598	data	_
42-6	6599-6603	were	_
42-7	6604-6613	processed	_
42-8	6614-6616	to	_
42-9	6617-6623	remove	_
42-10	6624-6627	the	_
42-11	6628-6634	linear	_
42-12	6635-6641	trends	_
42-13	6642-6645	and	_
42-14	6646-6654	filtered	_
42-15	6655-6660	using	_
42-16	6661-6668	typical	_
42-17	6669-6677	temporal	_
42-18	6678-6686	bandpass	_
42-19	6687-6688	(	_
42-20	6689-6698	0.01–0.08	_
42-21	6699-6701	Hz	_
42-22	6702-6703	)	_
42-23	6704-6706	to	_
42-24	6707-6713	reduce	_
42-25	6714-6717	the	_
42-26	6718-6731	low-frequency	_
42-27	6732-6737	drift	_
42-28	6738-6741	and	_
42-29	6742-6756	high-frequency	_
42-30	6757-6762	noise	_
42-31	6763-6764	.	_

Text=For calculating the DC, we performed voxel-wise voxel-based whole-brain correlation analysis on the pre-processed fMRI data, as described previously.
43-1	6765-6768	For	_
43-2	6769-6780	calculating	_
43-3	6781-6784	the	_
43-4	6785-6787	DC	_
43-5	6788-6789	,	_
43-6	6790-6792	we	_
43-7	6793-6802	performed	_
43-8	6803-6813	voxel-wise	_
43-9	6814-6825	voxel-based	_
43-10	6826-6837	whole-brain	_
43-11	6838-6849	correlation	_
43-12	6850-6858	analysis	_
43-13	6859-6861	on	_
43-14	6862-6865	the	_
43-15	6866-6879	pre-processed	_
43-16	6880-6884	fMRI	_
43-17	6885-6889	data	_
43-18	6890-6891	,	_
43-19	6892-6894	as	_
43-20	6895-6904	described	_
43-21	6905-6915	previously	_
43-22	6916-6917	.	_

Text=The time course of each voxel in each brain was correlated to every other voxel time course in the GM mask.
44-1	6918-6921	The	_
44-2	6922-6926	time	_
44-3	6927-6933	course	_
44-4	6934-6936	of	_
44-5	6937-6941	each	_
44-6	6942-6947	voxel	_
44-7	6948-6950	in	_
44-8	6951-6955	each	_
44-9	6956-6961	brain	_
44-10	6962-6965	was	_
44-11	6966-6976	correlated	_
44-12	6977-6979	to	_
44-13	6980-6985	every	_
44-14	6986-6991	other	_
44-15	6992-6997	voxel	_
44-16	6998-7002	time	_
44-17	7003-7009	course	_
44-18	7010-7012	in	_
44-19	7013-7016	the	_
44-20	7017-7019	GM	_
44-21	7020-7024	mask	_
44-22	7025-7026	.	_

Text=Thus, we could acquire a n × n matrix of Pearson's correlation coefficients between any pair of voxels, where n is the voxel number of the GM mask.
45-1	7027-7031	Thus	_
45-2	7032-7033	,	_
45-3	7034-7036	we	_
45-4	7037-7042	could	_
45-5	7043-7050	acquire	_
45-6	7051-7052	a	_
45-7	7053-7054	n	_
45-8	7055-7056	×	_
45-9	7057-7058	n	_
45-10	7059-7065	matrix	_
45-11	7066-7068	of	_
45-12	7069-7076	Pearson	_
45-13	7077-7079	's	_
45-14	7080-7091	correlation	_
45-15	7092-7104	coefficients	_
45-16	7105-7112	between	_
45-17	7113-7116	any	_
45-18	7117-7121	pair	_
45-19	7122-7124	of	_
45-20	7125-7131	voxels	_
45-21	7132-7133	,	_
45-22	7134-7139	where	_
45-23	7140-7141	n	_
45-24	7142-7144	is	_
45-25	7145-7148	the	_
45-26	7149-7154	voxel	_
45-27	7155-7161	number	_
45-28	7162-7164	of	_
45-29	7165-7168	the	_
45-30	7169-7171	GM	_
45-31	7172-7176	mask	_
45-32	7177-7178	.	_

Text=Next, we transformed the Pearson's correlation data into normally distributed Fisher Z-scores and constructed the whole-brain functional network by thresholding each correlation at r> 0.25.
46-1	7179-7183	Next	_
46-2	7184-7185	,	_
46-3	7186-7188	we	_
46-4	7189-7200	transformed	_
46-5	7201-7204	the	_
46-6	7205-7212	Pearson	_
46-7	7213-7215	's	_
46-8	7216-7227	correlation	_
46-9	7228-7232	data	_
46-10	7233-7237	into	_
46-11	7238-7246	normally	_
46-12	7247-7258	distributed	_
46-13	7259-7265	Fisher	_
46-14	7266-7274	Z-scores	_
46-15	7275-7278	and	_
46-16	7279-7290	constructed	_
46-17	7291-7294	the	_
46-18	7295-7306	whole-brain	_
46-19	7307-7317	functional	_
46-20	7318-7325	network	_
46-21	7326-7328	by	_
46-22	7329-7341	thresholding	_
46-23	7342-7346	each	_
46-24	7347-7358	correlation	_
46-25	7359-7361	at	_
46-26	7362-7363	r	_
46-27	7364-7365	>	_
46-28	7366-7370	0.25	_
46-29	7371-7372	.	_

Text=The threshold was the default setting while constructing the DC map.
47-1	7373-7376	The	_
47-2	7377-7386	threshold	_
47-3	7387-7390	was	_
47-4	7391-7394	the	_
47-5	7395-7402	default	_
47-6	7403-7410	setting	_
47-7	7411-7416	while	_
47-8	7417-7429	constructing	_
47-9	7430-7433	the	_
47-10	7434-7436	DC	_
47-11	7437-7440	map	_
47-12	7441-7442	.	_

Text=Only positive Pearson's correlation coefficients were considered in the present study.
48-1	7443-7447	Only	_
48-2	7448-7456	positive	_
48-3	7457-7464	Pearson	_
48-4	7465-7467	's	_
48-5	7468-7479	correlation	_
48-6	7480-7492	coefficients	_
48-7	7493-7497	were	_
48-8	7498-7508	considered	_
48-9	7509-7511	in	_
48-10	7512-7515	the	_
48-11	7516-7523	present	_
48-12	7524-7529	study	_
48-13	7530-7531	.	_

Text=For a given voxel, the DC was calculated as the sum of the significant connections at the individual level.
49-1	7532-7535	For	_
49-2	7536-7537	a	_
49-3	7538-7543	given	_
49-4	7544-7549	voxel	_
49-5	7550-7551	,	_
49-6	7552-7555	the	_
49-7	7556-7558	DC	_
49-8	7559-7562	was	_
49-9	7563-7573	calculated	_
49-10	7574-7576	as	_
49-11	7577-7580	the	_
49-12	7581-7584	sum	_
49-13	7585-7587	of	_
49-14	7588-7591	the	_
49-15	7592-7603	significant	_
49-16	7604-7615	connections	_
49-17	7616-7618	at	_
49-18	7619-7622	the	_
49-19	7623-7633	individual	_
49-20	7634-7639	level	_
49-21	7640-7641	.	_

Text=As described by previous studies, DC represents the number of direct connections for a given voxel in the voxel-based graphs.
50-1	7642-7644	As	_
50-2	7645-7654	described	_
50-3	7655-7657	by	_
50-4	7658-7666	previous	_
50-5	7667-7674	studies	_
50-6	7675-7676	,	_
50-7	7677-7679	DC	_
50-8	7680-7690	represents	_
50-9	7691-7694	the	_
50-10	7695-7701	number	_
50-11	7702-7704	of	_
50-12	7705-7711	direct	_
50-13	7712-7723	connections	_
50-14	7724-7727	for	_
50-15	7728-7729	a	_
50-16	7730-7735	given	_
50-17	7736-7741	voxel	_
50-18	7742-7744	in	_
50-19	7745-7748	the	_
50-20	7749-7760	voxel-based	_
50-21	7761-7767	graphs	_
50-22	7768-7769	.	_

Text=It has been widely used to represent the node characteristics of large-scale brain intrinsic connectivity networks.
51-1	7770-7772	It	_
51-2	7773-7776	has	_
51-3	7777-7781	been	_
51-4	7782-7788	widely	_
51-5	7789-7793	used	_
51-6	7794-7796	to	_
51-7	7797-7806	represent	_
51-8	7807-7810	the	_
51-9	7811-7815	node	_
51-10	7816-7831	characteristics	_
51-11	7832-7834	of	_
51-12	7835-7846	large-scale	_
51-13	7847-7852	brain	_
51-14	7853-7862	intrinsic	_
51-15	7863-7875	connectivity	_
51-16	7876-7884	networks	_
51-17	7885-7886	.	_

Text=Statistical analysis The differences in age, education, and nicotine use between the CCS-dependent and control groups were assessed by two-sample two-tailed t-tests using SPSS statistical software.
52-1	7887-7898	Statistical	_
52-2	7899-7907	analysis	_
52-3	7908-7911	The	_
52-4	7912-7923	differences	_
52-5	7924-7926	in	_
52-6	7927-7930	age	_
52-7	7931-7932	,	_
52-8	7933-7942	education	_
52-9	7943-7944	,	_
52-10	7945-7948	and	_
52-11	7949-7957	nicotine	_
52-12	7958-7961	use	_
52-13	7962-7969	between	_
52-14	7970-7973	the	_
52-15	7974-7987	CCS-dependent	_
52-16	7988-7991	and	_
52-17	7992-7999	control	_
52-18	8000-8006	groups	_
52-19	8007-8011	were	_
52-20	8012-8020	assessed	_
52-21	8021-8023	by	_
52-22	8024-8034	two-sample	_
52-23	8035-8045	two-tailed	_
52-24	8046-8053	t-tests	_
52-25	8054-8059	using	_
52-26	8060-8064	SPSS	_
52-27	8065-8076	statistical	_
52-28	8077-8085	software	_
52-29	8086-8087	.	_

Text=A two-tailed Pearson's chi-square test was performed to determine the differences in the gender between the two groups.
53-1	8088-8089	A	_
53-2	8090-8100	two-tailed	_
53-3	8101-8108	Pearson	_
53-4	8109-8111	's	_
53-5	8112-8122	chi-square	_
53-6	8123-8127	test	_
53-7	8128-8131	was	_
53-8	8132-8141	performed	_
53-9	8142-8144	to	_
53-10	8145-8154	determine	_
53-11	8155-8158	the	_
53-12	8159-8170	differences	_
53-13	8171-8173	in	_
53-14	8174-8177	the	_
53-15	8178-8184	gender	_
53-16	8185-8192	between	_
53-17	8193-8196	the	_
53-18	8197-8200	two	_
53-19	8201-8207	groups	_
53-20	8208-8209	.	_

Text=To examine the between-group differences in the DC using zDC maps, a two-sample t-test was performed between the two groups using REST.
54-1	8210-8212	To	_
54-2	8213-8220	examine	_
54-3	8221-8224	the	_
54-4	8225-8238	between-group	_
54-5	8239-8250	differences	_
54-6	8251-8253	in	_
54-7	8254-8257	the	_
54-8	8258-8260	DC	_
54-9	8261-8266	using	_
54-10	8267-8270	zDC	_
54-11	8271-8275	maps	_
54-12	8276-8277	,	_
54-13	8278-8279	a	_
54-14	8280-8290	two-sample	_
54-15	8291-8297	t-test	_
54-16	8298-8301	was	_
54-17	8302-8311	performed	_
54-18	8312-8319	between	_
54-19	8320-8323	the	_
54-20	8324-8327	two	_
54-21	8328-8334	groups	_
54-22	8335-8340	using	_
54-23	8341-8345	REST	_
54-24	8346-8347	.	_

Text=A correction for multiple comparisons was performed by Monte Carlo simulation using the AlphaSim program, (http: //afni.nimh.nih.gov).
55-1	8348-8349	A	_
55-2	8350-8360	correction	_
55-3	8361-8364	for	_
55-4	8365-8373	multiple	_
55-5	8374-8385	comparisons	_
55-6	8386-8389	was	_
55-7	8390-8399	performed	_
55-8	8400-8402	by	_
55-9	8403-8408	Monte	_
55-10	8409-8414	Carlo	_
55-11	8415-8425	simulation	_
55-12	8426-8431	using	_
55-13	8432-8435	the	_
55-14	8436-8444	AlphaSim	_
55-15	8445-8452	program	_
55-16	8453-8454	,	_
55-17	8455-8456	(	_
55-18	8457-8461	http	_
55-19	8462-8463	:	_
55-20	8464-8483	//afni.nimh.nih.gov	_
55-21	8484-8485	)	_
55-22	8486-8487	.	_

Text=The AlphaSim program was implemented in the REST software by combining the height threshold of P <0.001 and an extent threshold of P <0.01, which corresponded to a corrected P <0.01.
56-1	8488-8491	The	_
56-2	8492-8500	AlphaSim	_
56-3	8501-8508	program	_
56-4	8509-8512	was	_
56-5	8513-8524	implemented	_
56-6	8525-8527	in	_
56-7	8528-8531	the	_
56-8	8532-8536	REST	_
56-9	8537-8545	software	_
56-10	8546-8548	by	_
56-11	8549-8558	combining	_
56-12	8559-8562	the	_
56-13	8563-8569	height	_
56-14	8570-8579	threshold	_
56-15	8580-8582	of	_
56-16	8583-8584	P	_
56-17	8585-8586	<	_
56-18	8587-8592	0.001	_
56-19	8593-8596	and	_
56-20	8597-8599	an	_
56-21	8600-8606	extent	_
56-22	8607-8616	threshold	_
56-23	8617-8619	of	_
56-24	8620-8621	P	_
56-25	8622-8623	<	_
56-26	8624-8628	0.01	_
56-27	8629-8630	,	_
56-28	8631-8636	which	_
56-29	8637-8649	corresponded	_
56-30	8650-8652	to	_
56-31	8653-8654	a	_
56-32	8655-8664	corrected	_
56-33	8665-8666	P	_
56-34	8667-8668	<	_
56-35	8669-8673	0.01	_
56-36	8674-8675	.	_

Text=The average DC values of all voxels in the significantly different regions demonstrated by voxel-based analysis were extracted independently using the extract time series in REST and entered into SPSS.
57-1	8676-8679	The	_
57-2	8680-8687	average	_
57-3	8688-8690	DC	_
57-4	8691-8697	values	_
57-5	8698-8700	of	_
57-6	8701-8704	all	_
57-7	8705-8711	voxels	_
57-8	8712-8714	in	_
57-9	8715-8718	the	_
57-10	8719-8732	significantly	_
57-11	8733-8742	different	_
57-12	8743-8750	regions	_
57-13	8751-8763	demonstrated	_
57-14	8764-8766	by	_
57-15	8767-8778	voxel-based	_
57-16	8779-8787	analysis	_
57-17	8788-8792	were	_
57-18	8793-8802	extracted	_
57-19	8803-8816	independently	_
57-20	8817-8822	using	_
57-21	8823-8826	the	_
57-22	8827-8834	extract	_
57-23	8835-8839	time	_
57-24	8840-8846	series	_
57-25	8847-8849	in	_
57-26	8850-8854	REST	_
57-27	8855-8858	and	_
57-28	8859-8866	entered	_
57-29	8867-8871	into	_
57-30	8872-8876	SPSS	_
57-31	8877-8878	.	_

Text=Then, a Pearson's correlation analysis was performed to clarify the relationships between abnormal DC values of significantly different regions and clinical characteristics in CCS-dependent patients, including the duration of CCS usage, age at first CCS use, and BIS-11 scores; the significance levels were set at P <0.05 (two-tailed).
58-1	8879-8883	Then	_
58-2	8884-8885	,	_
58-3	8886-8887	a	_
58-4	8888-8895	Pearson	_
58-5	8896-8898	's	_
58-6	8899-8910	correlation	_
58-7	8911-8919	analysis	_
58-8	8920-8923	was	_
58-9	8924-8933	performed	_
58-10	8934-8936	to	_
58-11	8937-8944	clarify	_
58-12	8945-8948	the	_
58-13	8949-8962	relationships	_
58-14	8963-8970	between	_
58-15	8971-8979	abnormal	_
58-16	8980-8982	DC	_
58-17	8983-8989	values	_
58-18	8990-8992	of	_
58-19	8993-9006	significantly	_
58-20	9007-9016	different	_
58-21	9017-9024	regions	_
58-22	9025-9028	and	_
58-23	9029-9037	clinical	_
58-24	9038-9053	characteristics	_
58-25	9054-9056	in	_
58-26	9057-9070	CCS-dependent	_
58-27	9071-9079	patients	_
58-28	9080-9081	,	_
58-29	9082-9091	including	_
58-30	9092-9095	the	_
58-31	9096-9104	duration	_
58-32	9105-9107	of	_
58-33	9108-9111	CCS	_
58-34	9112-9117	usage	_
58-35	9118-9119	,	_
58-36	9120-9123	age	_
58-37	9124-9126	at	_
58-38	9127-9132	first	_
58-39	9133-9136	CCS	_
58-40	9137-9140	use	_
58-41	9141-9142	,	_
58-42	9143-9146	and	_
58-43	9147-9153	BIS-11	_
58-44	9154-9160	scores	_
58-45	9161-9162	;	_
58-46	9163-9166	the	_
58-47	9167-9179	significance	_
58-48	9180-9186	levels	_
58-49	9187-9191	were	_
58-50	9192-9195	set	_
58-51	9196-9198	at	_
58-52	9199-9200	P	_
58-53	9201-9202	<	_
58-54	9203-9207	0.05	_
58-55	9208-9209	(	_
58-56	9210-9220	two-tailed	_
58-57	9221-9222	)	_
58-58	9223-9224	.	_

